

Margaret H Collins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2757041/publications.pdf>

Version: 2024-02-01

76
papers

9,110
citations

94433

37
h-index

76900

74
g-index

79
all docs

79
docs citations

79
times ranked

4377
citing authors

#	ARTICLE	IF	CITATIONS
1	Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results From a Phase 3 Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 525-534.e10.	4.4	57
2	Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1488-1498.e11.	4.4	21
3	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 659-670.	2.9	40
4	Acquired Esophageal Strictures in Children: Morphometric and Immunohistochemical Analyses. <i>Pediatric and Developmental Pathology</i> , 2022, 25, 124-133.	1.0	6
5	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2022, 117, 264-271.	0.4	13
6	Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study. <i>Gastroenterology</i> , 2022, 162, 1635-1649.	1.3	21
7	Prospective Endoscopic Activity Assessment for Eosinophilic Gastritis in a Multisite Cohort. <i>American Journal of Gastroenterology</i> , 2022, 117, 413-423.	0.4	17
8	International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2474-2484.e3.	4.4	57
9	Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal Disease. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1598-1605.e2.	3.8	29
10	Impressions and aspirations from the FDA GREAT VI Workshop on Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis and Perspectives for Progress in the Field. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 844-853.	2.9	10
11	Development and Validation of Web-Based Tool to Predict Lamina Propria Fibrosis in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2022, 117, 272-279.	0.4	10
12	Eosinophilic Gastrointestinal Disorders: A new Path. <i>Pediatric and Developmental Pathology</i> , 2022, , 109352662210969.	1.0	0
13	A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 33-47.	2.9	5
14	A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. <i>Gastroenterology</i> , 2022, 163, 59-76.	1.3	33
15	Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 699-706.e4.	4.4	19
16	Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 473-483.e17.	4.4	54
17	Very early onset eosinophilic esophagitis is common, responds to standard therapy, and demonstrates enrichment for CAPN14 genetic variants. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 244-254.e6.	2.9	26
18	Machine Learning Approach for Biopsy-Based Identification of Eosinophilic Esophagitis Reveals Importance of Global features. <i>IEEE Open Journal of Engineering in Medicine and Biology</i> , 2021, 2, 218-223.	2.3	19

#	ARTICLE	IF	CITATIONS
19	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	0
20	Clinicopathologic Correlations in Eosinophilic Gastrointestinal Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3258-3266.	3.8	8
21	Desmoplakin and periplakin genetically and functionally contribute to eosinophilic esophagitis. <i>Nature Communications</i> , 2021, 12, 6795.	12.8	23
22	Identification of anoctamin 1 (ANO1) as a key driver of esophageal epithelial proliferation in eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 239-254.e2.	2.9	24
23	Monitoring Eosinophilic Esophagitis Disease Activity With Blood Eosinophil Progenitor Levels. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 70, 482-488.	1.8	10
24	Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 28-37.	2.9	17
25	High Patient Disease Burden in a Cross-sectional, Multicenter Contact Registry Study of Eosinophilic Gastrointestinal Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 71, 524-529.	1.8	19
26	An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 367-376.e3.	2.9	32
27	Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1629-1640.e4.	2.9	37
28	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , 2019, 37, 3243-3255.	1.6	61
29	Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1477-1488.e10.	4.4	16
30	Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. <i>Lancet, The</i> , 2019, 393, 1708-1720.	13.7	121
31	Prevalence of eosinophilic colitis and the diagnoses associated with colonic eosinophilia. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1928-1930.e3.	2.9	10
32	Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 666-673.e8.	4.4	51
33	Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. <i>Nature Communications</i> , 2019, 10, 38.	12.8	215
34	RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2019, 156, 592-603.e10.	1.3	182
35	Eosinophil progenitor levels correlate with tissue pathology in pediatric eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1221-1224.e3.	2.9	14
36	Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD). <i>Journal of Leukocyte Biology</i> , 2018, 104, 69-83.	3.3	34

#	ARTICLE	IF	CITATIONS
37	Eosinophilic esophagitis (EoE) genetic susceptibility is mediated by synergistic interactions between EoE-specific and general atopic disease loci. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1690-1698.	2.9	51
38	Histologic Correlates of Clinical and Endoscopic Severity in Children Newly Diagnosed With Ulcerative Colitis. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1127-1127.	3.7	3
39	Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 477-488.	8.1	135
40	Role of Vasoactive Intestinal Peptide in Promoting the Pathogenesis of Eosinophilic Esophagitis (EoE). <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 5, 99-100.e7.	4.5	13
41	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. <i>Gastroenterology</i> , 2018, 155, 1022-1033.e10.	1.3	712
42	Solute carrier family 9, subfamily A, member 3 (SLC9A3)/sodium-hydrogen exchanger member 3 (NHE3) dysregulation and dilated intercellular spaces in patients with eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1843-1855.	2.9	21
43	Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 130-138.e1.	2.9	45
44	Serologic Reactivity Reflects Clinical Expression of Ulcerative Colitis in Children. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1335-1343.	1.9	14
45	Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients. <i>Gastroenterology</i> , 2017, 152, 1345-1357.e7.	1.3	59
46	Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 855-868.	8.1	72
47	Histologic Correlates of Clinical and Endoscopic Severity in Children Newly Diagnosed With Ulcerative Colitis. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1491-1498.	3.7	31
48	Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2017, 152, 776-786.e5.	1.3	166
49	Creating a multi-center rare disease consortium – the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). <i>Translational Science of Rare Diseases</i> , 2017, 2, 141-155.	1.5	30
50	Eosinophilic Gastrointestinal Disorders Pathology. <i>Frontiers in Medicine</i> , 2017, 4, 261.	2.6	71
51	Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1842-1844.	4.4	19
52	Association of eosinophilic esophagitis and hypertrophic cardiomyopathy. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 934-936.e5.	2.9	12
53	Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2016, 150, 581-590.e4.	1.3	251
54	Angiogenesis and Vascular Endothelial Growth Factor-A Expression Associated with Inflammation in Pediatric Crohn's Disease. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 624-630.	1.7	19

#	ARTICLE	IF	CITATIONS
55	Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids. <i>MBio</i> , 2015, 6, e00647.	4.1	124
56	How Do Gastroenterologists Assess Overall Activity of Eosinophilic Esophagitis in Adult Patients?. <i>American Journal of Gastroenterology</i> , 2015, 110, 402-414.	0.4	44
57	Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1519-1528.e8.	2.9	118
58	Efficacy and Safety of Oral Budesonide Suspension in Pediatric Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 66-76.e3.	4.4	141
59	Histopathology of Eosinophilic Esophagitis. <i>Digestive Diseases</i> , 2014, 32, 68-73.	1.9	48
60	Development and Validation of a Symptom-Based Activity Index for Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2014, 147, 1255-1266.e21.	1.3	221
61	Histopathologic Features of Eosinophilic Esophagitis and Eosinophilic Gastrointestinal Diseases. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 257-268.	2.2	152
62	Efficacy, Dose Reduction, and Resistance to High-Dose Fluticasone in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2014, 147, 324-333.e5.	1.3	200
63	Trp53 Haploinsufficiency Modifies EGFR-Driven Peripheral Nerve Sheath Tumorigenesis. <i>American Journal of Pathology</i> , 2014, 184, 2082-2098.	3.8	26
64	Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1084-1092.e1.	2.9	218
65	Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1114-1124.	2.9	134
66	Molecular Diagnosis of Eosinophilic Esophagitis by Gene Expression Profiling. <i>Gastroenterology</i> , 2013, 145, 1289-1299.	1.3	212
67	Eosinophilic esophagitis: Updated consensus recommendations for children and adults. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 3-20.e6.	2.9	1,839
68	Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 160-165.e3.	2.9	236
69	Common variants at 5q22 associate with pediatric eosinophilic esophagitis. <i>Nature Genetics</i> , 2010, 42, 289-291.	21.4	397
70	Histopathology Associated with Eosinophilic Gastrointestinal Diseases. <i>Immunology and Allergy Clinics of North America</i> , 2009, 29, 109-117.	1.9	52
71	Clinical, Pathologic, and Molecular Characterization of Familial Eosinophilic Esophagitis Compared With Sporadic Cases. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 621-629.	4.4	103
72	Histopathologic Features of Eosinophilic Esophagitis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2008, 18, 59-71.	1.4	110

#	ARTICLE	IF	CITATIONS
73	IL-13 involvement in eosinophilic esophagitis: Transcriptome analysis and reversibility with glucocorticoids. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 1292-1300.	2.9	395
74	A Randomized, Double-Blind, Placebo-Controlled Trial of Fluticasone Propionate for Pediatric Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2006, 131, 1381-1391.	1.3	548
75	Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. <i>Journal of Clinical Investigation</i> , 2006, 116, 536-547.	8.2	750
76	Reply to Dr. C. Freeman et al.. <i>Medical and Pediatric Oncology</i> , 2003, 40, 341-341.	1.0	0